ʻO nā lāʻau hou no ka maʻi neʻe

Ma ka lā 15 o Mei, ua hoʻolaha ʻo Vanda Pharmaceuticals, kahi hui biopharmaceutical US, ua loaʻa i ka lua o ka Phase III ke aʻo ʻana i kāna lāʻau hou Tradipitant (tradipitant) no ka mālama ʻana i ka maʻi neʻe (ʻoi aku ka maʻi neʻe) ua loaʻa nā hopena maikaʻi.
ʻO Tradipitant kahi mea kūʻē neurokinin-1 (NK1) receptor antagonist i hoʻomohala ʻia e Eli Lilly. Ua loaʻa iā Vanda nā kuleana hoʻomohala honua o Tradipitant ma o ka laikini ʻana ma ʻApelila 2012.
I kēia manawa, ua hoʻomohala ʻo Vanda i ka Tradipitant no nā hōʻailona e like me ka atopic dermatitis pruritus, gastroparesis, ka maʻi coronavirus hou, ka maʻi neʻe, ka hoʻohui ʻana i ka waiʻona, ka phobia social, a me ka indigestion.
ʻO kēia haʻawina Phase 3 he 316 mau maʻi maʻi me ka mōʻaukala o ka maʻi neʻe, i mālama ʻia me 170 mg Tradipitant, 85 mg Tradipitant, a i ʻole placebo i ka wā o ka holo moku.
Ua loaʻa i nā mea aʻo a pau ka moʻolelo o ka maʻi kai. ʻO ka hopena mua o ke aʻo ʻana ʻo ka hopena o ka tradipitant (170 mg) ma ka luaʻi. ʻO nā kumu hope lua koʻikoʻi: (1) ka hopena o ka tradipitant (85 mg) i ka luaʻi; (2) ka hopena o ka tradipitant i ka pale ʻana i ka nausea nui a me ka luaʻi.
Ua hōʻike ʻia ʻo ka maʻi neʻe ʻana he mea pono ʻole i ka lāʻau lapaʻau. ʻAʻole ʻae ka US Food and Drug Administration (FDA) i kahi lāʻau lapaʻau hou no ka mālama ʻana i ka maʻi neʻe no nā makahiki ʻoi aku ma mua o 40 mai kona ʻae ʻana i ka scopolamine (kahi ʻāpana transdermal i waiho ʻia ma hope o ka pepeiao) i ka makahiki 1979.

Ma muli o ka ʻikepili mai nā haʻawina Phase III ʻelua, e hoʻouna ʻo Vanda i kahi noi kūʻai kūʻai no ka tradipitant i ka FDA no ka mālama ʻana i ka maʻi neʻe i ka hapahā ʻehā o 2024.